| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10008740 | Annals of Allergy, Asthma & Immunology | 2005 | 7 Pages |
Abstract
Olopatadine nasal spray (0.4% and 0.6%) provided statistically significant improvements in allergic rhinitis symptoms compared with placebo regarding TNSSs (reflective and instantaneous) and in quality-of-life variables in patients with SAR. Olopatadine nasal spray administered twice daily was safe and well tolerated in adolescents and adults.
Related Topics
Health Sciences
Medicine and Dentistry
Dermatology
Authors
Eli O. MD, Frank C. MD, Paul H. MD, David I. MD, Lawrence V. MD, William E. MD, Albert F. MD, Bradley F. MD, Peter S. MD, G.M. PhD, Michael J. PhD, Carolyn BSN, Susan L. MS, Lewis H. PhD, J. Rod MBA,